Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
VANQUISH-1 is fully enrolled with approximately 4,500 patients, and the Phase 3 oral program is expected to begin in Q3 2026, with maintenance dosing results also due that quarter
The Upper East Side neighborhood has one of the highest life expectancies and the lowest rates of diabetes and obesity in New York City, and yet prescriptions for GLP-1s are concentrated in that neighborhood
Results Disclaimer: Individual results vary based on starting weight, adherence to treatment, diet and exercise, genetic factors, and other variables
The degree of weight loss varies by medication and dose
The result is a complete triple-action approach: energy restoration, nerve repair, and healthy cell growth all at the same time
US$ 23.18
US$ 20.08
US$ 25.37
US$ 21.32
US$ 26.47
